Facts Matter – Episode Summary

Podcast: Facts Matter (The Epoch Times)
Episode Title: New COVID Variant Emerges in 25 States; FDA Launches New Side-Effect Reporting System
Date: April 3, 2026
Host: Roman

Episode Overview

In this episode, Roman examines two major public health developments: the U.S. FDA’s overhaul of its adverse event reporting systems and the emergence of two respiratory viruses in America—a novel COVID-19 variant dubbed "Cicada" and the human metapneumovirus (HMPV). The episode underscores transparency, data modernization, and vigilant monitoring of shifting public health trends.

Key Discussion Points & Insights

1. FDA Launches Unified Adverse Event Reporting System

[00:00 – 06:52]

• Background:

  • Previous adverse event reporting on FDA-regulated products was fragmented across multiple platforms: VAERS (vaccines), FAERS (drugs/cosmetics), AERS (animal drugs/foods), MAUDE (medical devices), and more.
  • These overlapping databases were described as convoluted, hard to search, and costly.

• Cost and Efficiency Factors:

  • The FDA Commissioner, Dr. Marty Makari, noted the old system cost taxpayers $37 million annually (00:54).
  • The new unified system, called AEMS (Adverse Event Monitoring System), aims to save $120 million over the next five years through technological consolidation, especially with artificial intelligence.
  • "Running these seven databases caused the American taxpayers roughly $37 million a year. ... This whole setup is no more." – Roman [01:34]

• Modernization Details:

  • AEMS provides a single, accessible platform for reporting and tracking side effects from all product categories (drugs, vaccines, cosmetics), with plans to expand to food and tobacco products by May.
  • AI assists with data digitization and real-time publication.
  • The FDA’s Chief AI Officer emphasized the “biggest technical transformation in agency history” enabled by an aggressive execution schedule (04:09).
  • "The team executed with perfection and delivered the biggest technical transformation in agency history. This is the new FDA." – FDA Chief AI Officer [04:18]

• User Instructions:

  • Public access is easy—search "AEMS" online for the direct link.

2. Human Metapneumovirus (HMPV) Surge

[06:53 – 12:45]

• Overview:

  • HMPV, a respiratory virus similar to the common cold (cough, fever, sore throat, congestion), is spreading throughout the U.S.
  • Particularly affects young children, older adults, and those with weakened immune systems.

• Symptoms and Risks:

  • Cases can progress to bronchitis or pneumonia in some individuals.
  • "There is no vaccine or treatment that can prevent HMPV infection, meaning you basically just have to suffer through it and make sure you stay hydrated, get some rest, and eat chicken soup." – Roman [08:06]
  • Hospitals provide supportive care: oxygen, IV fluids, rest.

• Current Trends & Data:

  • CDC reporting (late March): HMPV comprised 6.3% of positive respiratory virus samples—higher than COVID-19 and just below influenza [09:03].
  • Peaks expected in April, as flu cases decline.
  • Wastewater surveillance points to North California as a current hot spot.

• Future Prospects:

  • Nature (Feb 2026) published early research on a potential monoclonal antibody treatment for HMPV.
  • Mortality rate for most is similar to the flu; "no real reason for alarm" but parents and high-risk populations are advised to monitor symptoms [10:53].

3. “Cicada” – New COVID Variant (BA.3.2)

[12:46 – end]

• Emergence & Spread:

  • The BA.3.2 “Cicada” variant is an Omicron offshoot, first detected in South Africa (Nov 2024), now rising globally and in at least 25 U.S. states (New York, New Jersey, Connecticut, among others).
  • Nicknamed due to its “long hibernation and noisy return” (13:45).
  • “The Cicada variant now accounts for upwards of 30% of cases in some parts of Europe…and as of February 11, Cicada had been detected in four U.S. travelers and five patients, as well as airline and wastewater samples across 25 states.” – Roman, quoting CDC [15:04]

• Prevalence:

  • As of this episode, it represents only about 1% of U.S. cases, but is under close watch due to its features.

• Virology & Risk:

  • This variant’s spike protein contains 70–75 mutations—raising concerns about immune evasion and potential to spread despite prior infection or vaccination ("immune escape characteristics") [16:19].
  • Designated a “Variant of Interest” (VOI) by health authorities.

• Perspective on Threat:

  • Roman urges caution but not panic, noting close monitoring and providing resources for deeper research.
  • "Before we go ahead and shut down all of society once again, it should be worth noting…this new Cicada variant accounts for very little, something like 1% of all Covid cases." – Roman [14:23]

Memorable Quotes

• Dr. Marty Makari, FDA Commissioner ([01:24]):

  "The FDA's previous adverse event reporting systems were outdated and fragmented and made important data difficult to access. These clunky systems also wasted millions of taxpayer dollars and created blind spots in our post market surveillance of products... We're fixing the problem through a major modernization initiative."

• FDA Chief AI Officer ([04:18]):

  "Consolidating the FDA's adverse event systems and converting to real time publication was challenging, but made possible by a highly aggressive schedule. The team executed with perfection and delivered the biggest technical transformation in agency history. This is the new FDA."

• Roman, on HMPV ([08:06]):

  "There is no vaccine or treatment that can prevent HMPV infection, meaning that you basically just have to suffer through it and make sure you stay hydrated, get some rest and eat chicken soup."

• Roman, on COVID Cicada Variant ([14:23]):

  "Before we go ahead and shut down all of society once again, it should be worth noting…this new Cicada variant accounts for very little, something like 1% of all Covid cases."

Key Segment Timestamps

• 00:00 – 06:52: FDA’s adverse event reporting overhaul & AEMS
• 06:53 – 12:45: HMPV: Symptoms, risks, spread, and future treatments
• 12:46 – end: New COVID variant (Cicada/BA.3.2), mutations, geographic spread, impact

Closing Thoughts

Roman maintains the podcast’s signature tone—measured, fact-driven, and slightly informal—emphasizing vigilance over alarmism. He closes by encouraging viewers to stay informed, do their own research (with direct links provided), and, above all, “stay free.”